SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYGN -- Ignore unavailable to you. Want to Upgrade?

To: Moose who wrote (45)12/6/1999 7:01:00 PM
From: Jerome  Respond to of 135
 
This Stock has been all over the board the last week or so. I expect it to be up (and stay up) But who knows?

Here's the link:

biz.yahoo.com

Good Luck, Jerome



To: Moose who wrote (45)12/6/1999 7:06:00 PM
From: StaggerLee  Read Replies (1) | Respond to of 135
 
(I have to think this company will be acquired. We'll see what the call premiums look like tomorrow.)

FDA panel backs Cygnus diabetes glucose monitor

December 6, 1999 06:24 PM
GAITHERSBURG, Md., Dec 6 (Reuters) - Federal advisers on Monday backed a watch-like device by Cygnus Inc. CYGN designed to help diabetics keep better track of changes in their blood sugar.

A Food and Drug Administration advisory panel voted unanimously that the GlucoWatch was safe and effective for sale in the United States. The committee's support is important because the FDA usually follows the advice of its panels.

Cygnus said the device could provide painless measurements of blood sugar, or glucose, every 20 minutes for up to 12 hours. Better glucose information can help patients and their doctors adjust treatments to improve management of the disease.

Nearly 16 million Americans have diabetes, which can lead to serious complications such as blindness, limb loss and kidney damage.

Cygnus, based in Redwood City, Calif., recently announced it would sell most of the assets from its drug delivery business to a Johnson & Johnson unit and focus on developing the GlucoWatch.

REUTERS




To: Moose who wrote (45)12/7/1999 1:50:00 AM
From: tuck  Respond to of 135
 
Moose,

Even if Auric's crew is unfazed, most shorts will be -- and that's all it will take with the short ratio where it is. As of 11/8/99, it was 7.62 according to Yahoo! I would guess it is higher now. The GlucoWatch addresses a huge market, and only needs to get a small chunk of it to allow CYGN to succeed. The math has been done in earlier posts here. In my humble opinion, there won't be any sell on the news effect here.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News